General Press Coverage:
In an in-depth 15 minute feature interview, Universities Allied for Essential Medicines (UAEM) North America’s Executive Director Merith Basey speaks on The Zero Hour with RJ Eskow, spreading UAEM’s core message of publicly funded medicines being affordable to the public, using the story of insulin as a cautionary tale, while condemning the nomination of Alex Azar to US Secretary of Health and Human Services.
A growing insulin crisis adds urgency to efforts to radically reform the prescription drug pipeline.
As an exhibit of everything wrong with our corporatized health-care system, Donald Trump’s first Health and Human Services secretary is a tough act to follow. Less a pharma a bro than a pharma granddad, Tom Price invested in drug makers while serving as their loyal guard dog in congress, where he ferociously protected their public funding and bloated profit margins against regular threats.
The Medicines Patent Pool announced today that it has signed a license agreement with Johns Hopkins University for a candidate tuberculosis treatment. Although seen as a major step forward by public health groups, they said the agreement does not include guarantees that the treatment that could be brought to the market would be affordable for all.
The six candidates for Director-General of the World Health Organization (WHO) – of whom one will be elected this May – have published responses to an open letter asking them to make clear their plans for the future of the WHO’s work in promoting a new system of equitable drug R&D. The original open letter was signed by 18 civil society organizations, and titled “Will you support a patient-centred R&D agreement?“.
A range of civil society organisations have issued a public statement opposing the United States Army’s proposed grant of an exclusive licence on technology necessary to produce a Zika vaccine to French pharmaceutical company Sanofi.
“If universities use federal funds to help invent new medicines, shouldn’t they also push to make sure people who need those medicines get them? That’s the idea behind Universities Allied for Essential Medicines. Tavera, now an M.D./Ph.D. student at Case Western Reserve University, is a founding member and the current president of the organization, which has 100 chapters at universities in 18 different countries.”
If the McGill chapter’s motion passes on November 7 at the GA, the motion will push the University to “adopt an open access framework for all future medicine patents created at McGill and sold to the private sector.”…..
UAEM advocates for access to medicine in many ways, with a few specific student chapter-led campaigns and projects. One campaign, called “Take Back Our Meds,” targets“the National Institutes of Health (NIH) … to ensure that the research they fund at universities [that] leads to a product being developed” is made accessible and affordable to patients both domestically and abroad…..
Other98 and allies from Social Security Works, Act Up, and Universities Allied for Essential Medicines have teamed up to create an infotaining new website……featuring a series of text message exchanges between a fictional (but accurate) Pharma CEO and everyman John Doe.
Activists targeted candidate Clinton for her refusal to renew her 2008 campaign pledges to regulate the price-gouging of medicines made by major pharmaceutical companies……… The high prices make it hard for people with HIV as well as other people to access the lifesaving treatment they need.
This current system is very well-designed to do exactly what it does: create maximum profits for pharmaceutical companies. And it has been incredibly resilient to every challenge we make to it.
May 26th, 2016
Public health advocates… had high hopes that this year’s [WHA] could finally agree on some alternative ways to fund [R&D] that can lead to affordable medical products by de-linking R&D costs from prices, through the long-awaited discussion of a landmark 2012 report of a WHO expert group [CEWG] on medical R&D.
Consumer Groups Object to FDA Reforms in Cures Bill
May 19th, 2016
Thirteen consumer and patient groups May 18 warned members of a Senate committee not to insert proposals in their version of the 21st Century Cures Act that would undermine patient safety and curb access to lifesaving treatments.
Public Health Advocates Urge WHO Action on R&D Financing for the Poor
May 12th, 2016
Public health advocates last week told World Health Organization delegates they must act quickly to save the lives of poor populations suffering from less common diseases for which there is no research and development funding.
February 25th, 2016
Re:Route, a mapping tool that lays out the research and development (R&D) landscape of innovation and financing for medicines, has been launched by the Universities Allied for Essential Medicines (UAEM). It is a one-stop place for the alternative biomedical research and development landscape.
November 13th, 2015
May 21st, 2015
Investigadores y estudiantes se unen para pedir un Acuerdo Global sobre I+D a la OMS y los Estados Miembros
6 Noviembre 2015
Estudiantes e investigadores piden un pacto mundial para el acceso asequible a fármacos.
Investigadores y estudiantes se unen para pedir un Acuerdo Global sobre I+D a la OMS y los Estados Miembros [Spain; RADIO]
10 Noviembre 2015
Científicos e investigadores están firmando una carta abierta dirigida a la Organización Mundial de la Salud (OMS) y a los Estados miembros, pidiendo un Acuerdo global sobre I+D.
Die Organisation „Universities Allied for Essential Medicines“ macht das geltende Patentsystem für überhöhte Preise und damit für Zugangshürden zu medizinischen Innovationen verantwortlich. Sie plädiert für alternative Forschungsanreize.
Studerende kæmper globalt for billigere medicin [Denmark; RADIO]
3 November 2015
Canadian Report Card Media Coverage in 2017-2018:
The Lancet Global Health Blog
January 12th, 2018
In the current biomedical research and development (R&D) system, exclusive IP rights and profit are the primary incentives for creating new drugs. As a direct consequence of this model, as estimated 10 million people die every year because they cannot access life-saving medicines. Existing medicines are often priced out of reach, and many treatments do not exist at all simply because the disease in question affects patients too poor to constitute a market worth investing for. This is a global market and policy failure. How can universities be a part of the solution?
October 24th, 2017
UAEM’s 2017 Canadian University Report Card on Global Equity in Biomedical Research explores how well universities are currently performing. While some universities have made progress, there is a long way to go. A national-level Canadian Institute for Health Information policy would speed up the process and close the gap between those able to afford medicines and those suffering because they cannot, both at home and internationally.
Canadian Medical Association Journal Blogs
October 23rd, 2017
This is the 5th iteration of the report card, but the first time UAEM focused exclusively on public research schools (and exclusively on Canada, for that matter). While there were some promising highlights of what our universities can do when they set themselves to it, overall it is clear that Canadian schools are failing to use their considerable power to address many neglected aspects of global health.
Intellectual Property Watch
October 3rd, 2017
The Universities Allied for Essential medicines (UAEM) evaluated 15 Canadian research-intensive universities on their contributions to biomedical research on neglected health needs, access to medicines, and education concerning access and innovation issues. The results show that for a number of those universities, this contribution is sub-optimal.
Report Card Media Coverage in 2015:
The New York Times
May 11th, 2015
For the second time, American universities have been ranked by how well they do global health research. This time only one — Johns Hopkins — earned a grade as high as A minus.
The Lancet Global Health Blog
April 20th, 2015
The University Report Card: Global Equity and Biomedical Research… serves as an advocacy tool for universities to assess their own progress in investing in innovative medical research that addresses global neglected health needs, as well as focusing on the core role of universities in terms of transforming innovation and access for all.
Additional 2015 Articles:
Advisory Board Company
UCSD’s San Diego Union Tribune
Johns Hopkins Center for Global Health
Johns Hopkins Hub
Boston University Daily Free Press
The Huffington Post
The Daily Pennsylvanian
Report Card Media Coverage in 2013:
The New York Times
BMJ (British Medical Journal)
Interpress Service News Agency
The Chronicle of Higher Education
The Toronto Star
The Kaiser Family Foundation
University of Florida Alligator
The Daily Iowan
University of British Columbia
The Vancouver Sun
The University of Alberta Gateway
The Boston University Daily Free Press
The Duke Chronicle–News
Triangle Business Journal
The Duke Chronicle–Editorial
The Times of India
The University of Minnesota, Twin Cities, Minnesota Daily
New York University’s Washington Square News
The Marquette Tribune
Minnesota Public Radio on Campus
The Dartmouth Daily
The Pitt News
Georgetown University O’Neill Institute
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.